Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 2 selected

Type

Guidance programme 3 selected

Guidance programme

Area of interest

Showing 11 to 20 of 985

TitleReference numberPublishedLast updated
Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)TA1144
Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopauseTA1143
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophilsTA1142
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and overTA1140
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)TA1141
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatmentTA1139
Pegzilarginase for treating arginase-1 deficiency in people 2 years and overHST35
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancerTA1138
Molnupiravir for treating COVID-19TA1056
Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19TA878

Results per page

  1. 10
  2. 25
  3. 50
  4. All